SCHEMBL20704864

SCHEMBL20704864

COc1cc(OC)c2c(=O)c(C(=O)Nc3cc(OC)c(OC)c(OC)c3)c[nH]c2c1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ TUBB1 Q9H4B7 1/20 0.46
▸ ALDH1A1 P00352 4/20 0.46
▸ HTT P42858 2/20 0.46
▸ LMNA P02545 1/20 0.46
▸ TP53 P04637 3/20 0.44
▸ SMN1; SMN2 Q16637 4/20 0.44
▸ HPGD P15428 1/20 0.44
▸ L3MBTL1 Q9Y468 1/20 0.44
▸ PKM P14618 2/20 0.43
▸ TDP1 Q9NUW8 2/20 0.43
▸ TOP1 P11387 1/20 0.42
▸ ATM Q13315 1/20 0.42
▸ NPC1 O15118 1/20 0.42
▸ RAB9A P51151 1/20 0.42
▸ MEN1 O00255 2/20 0.42
▸ KMT2A Q03164 2/20 0.42
▸ MAPT P10636 2/20 0.41
▸ CISD2 Q8N5K1 1/20 0.41
▸ THRB P10828 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20704950 0.92 NPC1 (0.45) TUBB1ALDH1A1HTTLMNATP53
SCHEMBL20704836 0.88 MTNR1A (0.47) TUBB1ALDH1A1HTTLMNATP53
SCHEMBL20704636 0.86 CFTR (0.55) ALDH1A1LMNASMN1; SMN2HPGDNPC1
SCHEMBL20704811 0.85 KMT2A (0.52) ALDH1A1LMNASMN1; SMN2HPGDNPC1
SCHEMBL20704573 0.82 MAOB (0.50) ALDH1A1LMNATP53SMN1; SMN2NPC1
SCHEMBL20711028 0.82 TUBB1 (0.49) TUBB1LMNAMEN1KMT2A
SCHEMBL20704897 0.81 CFTR (0.46) LMNASMN1; SMN2HPGDNPC1RAB9A
SCHEMBL20704906 0.79 TUBB1 (0.46) TUBB1LMNATP53L3MBTL1MAPT
SCHEMBL20704965 0.79 ALDH1A1 (0.48) TUBB1ALDH1A1HTTSMN1; SMN2HPGD
SCHEMBL20704840 0.78 CFTR (0.54) ALDH1A1HTTLMNATP53SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230113225-A1 INHIBITORS OF MICROBIALLY INDUCED AMYLOID AXIAL THERAPEUTICS, INC. (US) 2023-04-13 — — US disclosed
US-20230103887-A1 INHIBITORS OF MICROBIALLY INDUCED AMYLOID AXIAL THERAPEUTICS, INC. (US) 2023-04-06 — — US disclosed
US-11505528-B2 Inhibitors of microbially induced amyloid AXIAL THERAPEUTICS, INC. (US) 2022-11-22 — — US disclosed
US-11505528-B2 Inhibitors of microbially induced amyloid AXIAL THERAPEUTICS, INC. (US) 2022-11-22 — — US disclosed
WO-2022098879-A1 SUSTAINED RELEASE SOLID DOSAGE FORMS FOR MODULATING THE COLONIC MICROBIOME AXIAL THERAPEUTICS, INC. (US) 2022-05-12 — — WO disclosed
US-20220133634-A1 SUSTAINED RELEASE SOLID DOSAGE FORMS FOR MODULATING THE COLONIC MICROBIOME AXIAL THERAPEUTICS, INC. (US) 2022-05-05 — — US disclosed
US-20210052503-A1 SUSTAINED RELEASE SOLID DOSAGE FORMS FOR MODULATING THE COLONIC MICROBIOME AXIAL THERAPEUTICS, INC. (US) 2021-02-25 — — US disclosed
WO-2020227437-A1 SUSTAINED RELEASE SOLID DOSAGE FORMS FOR MODULATING THE COLONIC MICROBIOME AXIAL BIOTHERAPEUTICS, INC. (US) 2020-11-12 — — WO disclosed
US-20200290970-A1 INHIBITORS OF MICROBIALLY INDUCED AMYLOID AXIAL BIOTHERAPEUTICS, INC. (US) 2020-09-17 — — US disclosed
US-20200290970-A1 INHIBITORS OF MICROBIALLY INDUCED AMYLOID AXIAL BIOTHERAPEUTICS, INC. (US) 2020-09-17 — — US disclosed
EP-3664822-A1 INHIBITORS OF MICROBIALLY INDUCED AMYLOID Axial Biotherapeutics, Inc. (US) 2020-06-17 — — EP disclosed
WO-2019028456-A1 INHIBITORS OF MICROBIALLY INDUCED AMYLOID AXIAL BIOTHERAPEUTICS, INC. (US) 2019-02-07 — — WO disclosed
WO-2019028456-A1 INHIBITORS OF MICROBIALLY INDUCED AMYLOID AXIAL BIOTHERAPEUTICS, INC. (US) 2019-02-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230103887-A1 INHIBITORS OF MICROBIALLY INDUCED AMYLOID SNCA, PARK7, PRNP TUBB1 241/4885ALDH1A1 4090/4885HTT 16/4885
US-11505528-B2 Inhibitors of microbially induced amyloid SNCA, PARK7, PRNP TUBB1 241/4885ALDH1A1 4090/4885HTT 16/4885
US-20230113225-A1 INHIBITORS OF MICROBIALLY INDUCED AMYLOID SNCA, PARK7, PRNP TUBB1 305/4885ALDH1A1 4129/4885HTT 22/4885
US-20210052503-A1 SUSTAINED RELEASE SOLID DOSAGE FORMS FOR MODULATING THE COLONIC MICROBIOME APC, SNCA, PARK7 TUBB1 1204/4885ALDH1A1 1812/4885HTT 23/4885
US-20220133634-A1 SUSTAINED RELEASE SOLID DOSAGE FORMS FOR MODULATING THE COLONIC MICROBIOME APC, SNCA, PARK7 TUBB1 1204/4885ALDH1A1 1812/4885HTT 23/4885
US-20200290970-A1 INHIBITORS OF MICROBIALLY INDUCED AMYLOID SNCA, PARK7, PRNP TUBB1 241/4885ALDH1A1 4090/4885HTT 16/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback